Optimisation of an oviposition protocol employing human chorionic and pregnant mare serum gonadotropins in the Barred Frog Mixophyes fasciolatus (Myobatrachidae)

Table 3 Oviposition by female M. fasciolatus after various mammalian gonadotropin treatments

Treatment groups	Day, time & number of females ovipositing																					Oviposition (%)*
Day	1				2				3				4				5				6
Light/dark (24 hr)**	D	L	L	D	D	L	L	D	D	L	L	D	D	L	L	D	D	L	L	D	D
(1) Control – Saline only: 4 injections
Saline																						0/6 (0%)
(2) hCG only
hCG 900									6													6/20 (30%)
hCG 1050-1400									1				1	1	1							4/17 (23.5%)
All hCG only																						10/37 (27%)
(3) hCG and pituitary glands
hCG 1200–1500 + 6 pituitaries									1	1												2/7 (29%)
(4) PMSG and hCG (200 IU)*
50 PMSG; -3 days						1																1/6 (17%)
75 PMSG;-4, -2 days****										4												4/12 (33%)
75 PMSG;-5, -3 days****									6	6		1	6				1				1	21/41 (51%)
75 PMSG;-6, -4 days****					1			1	1				1	1			1					6/9 (67%)
All PMSG and hCG (200 IU)																						32/68 (47%)

Oviposition by female M. fasciolatus after either (1) sham injections with saline (2) injections with human chorionic gonadotropin (hCG) only (3) injections with human gonadotropin and 6 amphibian pituitary glands (B. marinus) (4) injection with pregnant mare serum gonadotropin (PMSG) indicated number of days before administration of first of two doses of human chorionic gonadotropin. * Number ovipositing/Number treated (% ovipositing) ** Light/Dark cycle = 12 hr L: 12 hr D; each L or D represents 6 hrs ***hCG = 100 IU administered on each of days 1 and 2. **** Where PMSG total dose = 75 IU: first dose = 50 IU; second dose = 25 IU administered on the indicated number of days before the first dose of hCG.

ISSN: 1477-7827